Literature DB >> 1907735

Sustained pharmacological activities in rats following single and repeated administration of once-a-month injectable microspheres of leuprolide acetate.

H Okada1, T Heya, Y Ogawa, H Toguchi, T Shimamoto.   

Abstract

Once-a-month injectable microspheres of leuprolide acetate prepared with copoly(DL-lactic/glycolic acid) using an in-water drying method were assessed for duration of the analogue release and pharmacological effects in rats after a single or repeated injection. The periodic challenge test revealed that a single injection of the microspheres caused a dramatic and persistent suppression of the ability of the pituitary-gonadal system to secrete gonadotropin and testosterone for over 5 weeks. The complete recovery of these functions was observed 10 weeks after the injection. The repeated injection of the microspheres at intervals of 2 or 4 weeks achieved persistent suppression of steroidogenesis after an initial transient flare-up and beneficially avoided the "acute-on-chronic response." This depot formulation is expected to assure patient compliance and produce stronger therapeutic effects than the daily solution.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1907735     DOI: 10.1023/a:1015844421319

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  14 in total

1.  Luteinizing hormone-releasing hormone-induced regulation of gonadotropin and prolactin receptors in the rat testis.

Authors:  K J Catt; A J Baukal; T F Davies; M L Dufau
Journal:  Endocrinology       Date:  1979-01       Impact factor: 4.736

2.  A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or copoly(lactic/glycolic) acid.

Authors:  Y Ogawa; M Yamamoto; H Okada; T Yashiki; T Shimamoto
Journal:  Chem Pharm Bull (Tokyo)       Date:  1988-03       Impact factor: 1.645

3.  In vivo release profiles of leuprolide acetate from microcapsules prepared with polylactic acids or copoly(lactic/glycolic) acids and in vivo degradation of these polymers.

Authors:  Y Ogawa; H Okada; M Yamamoto; T Shimamoto
Journal:  Chem Pharm Bull (Tokyo)       Date:  1988-07       Impact factor: 1.645

4.  One-month release injectable microcapsules of a luteinizing hormone-releasing hormone agonist (leuprolide acetate) for treating experimental endometriosis in rats.

Authors:  H Okada; T Heya; Y Ogawa; T Shimamoto
Journal:  J Pharmacol Exp Ther       Date:  1988-02       Impact factor: 4.030

5.  Desensitization of gonadotropin-releasing response following vaginal consecutive administration of leuprolide in rats.

Authors:  H Okada; I Yamazaki; Y Sakura; T Yashiki; T Shimamoto; H Mima
Journal:  J Pharmacobiodyn       Date:  1983-07

6.  Controlled release of a luteinizing hormone-releasing hormone analogue from poly(d,l-lactide-co-glycolide) microspheres.

Authors:  L M Sanders; J S Kent; G I McRae; B H Vickery; T R Tice; D H Lewis
Journal:  J Pharm Sci       Date:  1984-09       Impact factor: 3.534

7.  Regression of rat mammary tumors by a potent luteinizing hormone-releasing hormone analogue (leuprolide) administered vaginally.

Authors:  H Okada; Y Sakura; H Kawaji; T Yashiki; H Mima
Journal:  Cancer Res       Date:  1983-04       Impact factor: 12.701

8.  Potential new treatment of endometriosis: reversible inhibition of pituitary-ovarian function by chronic intranasal administration of a luteinizing hormone-releasing hormone (LH-RH) agonist.

Authors:  A Lemay; G Quesnel
Journal:  Fertil Steril       Date:  1982-09       Impact factor: 7.329

9.  Antireproductive effects of a potent gonadotropin-releasing hormone antagonist in the male rat.

Authors:  C Rivier; J Rivier; W Vale
Journal:  Science       Date:  1980-10-03       Impact factor: 47.728

10.  Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone.

Authors:  T W Redding; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1981-10       Impact factor: 11.205

View more
  9 in total

1.  In vitro characterization and in vivo testosterone suppression of 6-month release poly(D,L-lactide) leuprolide microspheres.

Authors:  Byung Ho Woo; Kyu-Heum Na; Bhas A Dani; Ge Jiang; B C Thanoo; Patrick P DeLuca
Journal:  Pharm Res       Date:  2002-04       Impact factor: 4.200

Review 2.  Clinical pharmacokinetics of depot leuprorelin.

Authors:  Piero Periti; Teresita Mazzei; Enrico Mini
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  Self-healing microencapsulation of biomacromolecules without organic solvents.

Authors:  Samuel E Reinhold; Kashappa-Goud H Desai; Li Zhang; Karl F Olsen; Steven P Schwendeman
Journal:  Angew Chem Int Ed Engl       Date:  2012-09-26       Impact factor: 15.336

4.  Pharmacokinetics of once-a-month injectable microspheres of leuprolide acetate.

Authors:  H Okada; Y Inoue; T Heya; H Ueno; Y Ogawa; H Toguchi
Journal:  Pharm Res       Date:  1991-06       Impact factor: 4.200

5.  Sustained activity and release of leuprolide acetate from an in situ forming polymeric implant.

Authors:  H B Ravivarapu; K L Moyer; R L Dunn
Journal:  AAPS PharmSciTech       Date:  2000-02-28       Impact factor: 3.246

6.  Preparation of three-month depot injectable microspheres of leuprorelin acetate using biodegradable polymers.

Authors:  H Okada; Y Doken; Y Ogawa; H Toguchi
Journal:  Pharm Res       Date:  1994-08       Impact factor: 4.200

7.  Sustained suppression of the pituitary-gonadal axis by leuprorelin three-month depot microspheres in rats and dogs.

Authors:  H Okada; Y Doken; Y Ogawa; H Toguchi
Journal:  Pharm Res       Date:  1994-08       Impact factor: 4.200

8.  Dose and load studies for subcutaneous and oral delivery of poly(lactide-co-glycolide) microspheres containing ovalbumin.

Authors:  T Uchida; S Martin; T P Foster; R C Wardley; S Grimm
Journal:  Pharm Res       Date:  1994-07       Impact factor: 4.200

Review 9.  Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders.

Authors:  G L Plosker; R N Brogden
Journal:  Drugs       Date:  1994-12       Impact factor: 9.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.